Mezigdomide plus Dexamethasone in Relapsed and Refractory …
2023年8月30日 · Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those...
Mezigdomide | International Myeloma Foundation
2024年5月8日 · What Is Mezigdomide? Mezigdomide is a CELMoD agent that is being studied in many clinical trials with different drug combinations and in different myeloma patient populations. What Are CELMoDs? Cereblon (CRBN) E3 ligase modulators (CELMoDs) are …
Potent Immunotherapy Pill Shows Promise for Certain Multiple …
2023年9月25日 · This powerful dual action makes mezigdomide more potent against myeloma than similar drugs known as immunomodulators or IMiD agents, which work by a similar but otherwise distinct mechanism, pre-clinical research has shown.
SUCCESSOR-2 Clinical Trial Information | Bristol Myers Squibb
Learn more about the SUCCESSOR-2 clinical trial of mezigdomide in people with relapsed/refractory multiple myeloma with at least one prior treatment and with lenalidomide and anti-CD38 mAb exposure.
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase …
2022年11月15日 · Introduction: Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and …
2023年8月30日 · Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant...
Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma
2023年8月30日 · Mezigdomide targets cereblon, the long-sought binding partner for thalidomide, which failed notoriously as a sedative for use during pregnancy but found a home as the first highly active...
Mezigdomide Plus Tazemetostat and Dexamethasone Is Effective …
2024年9月30日 · The novel, all-oral combination regimen of mezigdomide (CC-92480), tazemetostat (Tazverik), and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients...
Clinical Trials Using Mezigdomide - NCI - National Cancer Institute
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a …
Mezigdomide Shows Encouraging Activity With Dexamethasone …
2022年12月11日 · Mezigdomide (CC-92480), a potent novel CELMoD compound with a differentiated preclinical profile from immunomodulatory agents, showed notable clinical activity and a manageable safety profile...